Quince Therapeutics, Inc. annual report, FY2019

Quince Therapeutics, Inc. — filing identity and period

Important identity discrepancy: The supplied filing is Cortexyme, Inc.’s Form 10-K, not a filing for Quince Therapeutics, Inc. The company reported fiscal-year results through December 31, 2019; this is not a standalone fourth-quarter report. Cortexyme filed the report on March 16, 2020.

Business context

Cortexyme was a clinical-stage biopharmaceutical company developing COR388, an oral gingipain inhibitor, for Alzheimer’s disease. Its global Phase 2/3 GAIN trial began in 2019, targeting approximately 570 patients. The company had no approved products or product sales and depended on external financing to fund development.

Financial results and liquidity

No revenue or profit margins were reported; profitability metrics are not meaningful for this pre-commercial company. R&D expense increased 199.6%, mainly as GAIN advanced. G&A expense rose 340.2%, reflecting increased staffing and public-company costs. Cash provided by financing was $77.4 million, including $77.8 million net IPO proceeds. Investment purchases and maturities drove $17.7 million of investing cash outflow.

At year-end, total assets were $124.4 million, current assets $106.1 million, current liabilities $8.9 million, and stockholders’ equity $115.5 million. The filing reports no outstanding debt at year-end; liabilities were primarily accounts payable and accrued expenses. The company stated it expected existing resources to fund planned operations through at least 2021, subject to assumptions and spending needs. In February 2020, it raised $125 million gross, approximately $117.6 million net, in a private placement.

Material changes and notable items

• The May 2019 IPO raised approximately $77.8 million net. Preferred shares converted into common stock; year-end common shares outstanding rose to 26.9 million from 3.4 million.
• Accumulated deficit increased to $69.8 million from $32.8 million.
• Adoption of lease accounting in 2019 resulted in a $0.9 million right-of-use asset and corresponding lease liabilities at adoption; the South San Francisco office lease was prepaid.
• The company reported remediation during 2019 of a previously disclosed material weakness in internal control over financial reporting. Management concluded disclosure controls were effective at year-end; the 10-K included no management ICFR assessment or auditor attestation due to transition exemptions.
• The audited financial statements received an unqualified opinion. The auditor noted the 2019 change in lease accounting; it did not opine on internal-control effectiveness.

Outlook, commentary and key risks

• Management planned a GAIN interim analysis after approximately 100 patients in each of three arms completed six months of treatment, targeted by the end of 2020, and top-line results by the end of 2021. These were forward-looking plans, not reported outcomes.
• Early Phase 1 findings were based on 67 participants, including nine Alzheimer’s patients. The filing cautioned that exploratory cognitive improvements were not uniformly statistically significant and should be interpreted carefully.
• The FDA had imposed a partial clinical hold limiting exposure at doses substantially above the planned GAIN top dose; the planned trial doses were permitted to proceed.
• Major risks include GAIN’s uncertain efficacy and safety, reliance on COR388, the unproven disease hypothesis, trial enrollment and execution, third-party manufacturing, regulatory approval, intellectual-property protection, competition, and need for future capital.
• The filing identified the emerging coronavirus outbreak as a possible source of clinical-enrollment and supply-chain delays. The company also warned that financing needs could exceed expectations and that additional funding might not be available on acceptable terms.
• No material pending litigation was reported. The company had no commercial products, sales infrastructure, or history of profitability.

Investor facts to verify

1. Confirm the issuer: this document is Cortexyme, Inc.’s 2019 10-K, despite the request metadata naming Quince Therapeutics.
2. Check subsequent filings for GAIN trial progress, results, regulatory developments, and any changes to the stated timelines.
3. Verify cash runway using subsequent spending, financing, and investment balances; include the February 2020 private placement and its dilution.
4. Review later disclosures on the FDA partial hold, dose limits, safety findings, and manufacturing supply.
5. Assess the strength and limitations of the small Phase 1 patient dataset and the company’s underlying scientific hypothesis.
6. Review the 10-K’s complete financial statements and notes for equity compensation, share issuance, commitments, and control remediation details.